AKT1 and cancer: Lupeol has been shown to sensitize cancer therapy-resistant cells by modulating various inflammatory cytokines such as IL-6, TNF-α, IFN-γ and also BAX, BCL-2, FAS, Caspases, Survivin, and PI3K-AKT-mTOR pathways and Cyclins, CDKs, P21, P53, and PCNA molecules, which are involved in cell cycle regulation [36].